You know the drill. Eat vegetables. Lift heavy things. Try to get eight hours of sleep. Ignore the stress, or at least breathe through it.
These are the pillars. But here’s the problem with generic advice: it doesn’t tell you if you’re actually winning.
Knowing the basics is one thing. Knowing what to measure to prove those choices are working is another. In 2026, the tools to track your biological trajectory are more accessible than ever. But they aren’t all created equal.
Tracking data creates a feedback loop. It turns abstract wellness goals into concrete actions. It catches subtle trends before they become medical emergencies.
As a physician operating at the intersection of clinical care and longevity science, I see people chase novelty. They buy the flashiest gadget. They order the most expensive blood panel. Often, they get anxious.
Here is what the evidence actually says about tracking health and aging. No fluff. Just data.
Blood Biomarkers That Actually Predict Mortality
Routine bloodwork is the backbone of preventive medicine. If you haven’t had a CBC or cholesterol check since your first annual physical, start there. Most adults need baseline screening around age 20.
But if you want to predict mortality, you need to go deeper. Longevity-focused panels look at markers with robust longitudinal data.
Apolipoprotein B (ApoB) is the big one. The 2026 ACC/AHA Dislipidemia Guidelines formally recommend it. Why? It predicts atherosclerotic cardiovascular disease (ASCVD) risk more accurately than LDL-C. This is especially true if you have diabetes or triglycerides above 150 mg/dL.
Then there is high-sensitivity C-reactive protein (hsPCR). One study showed that a single hsCRP measurement provides a wider spread of cardiovascular risk over 30years than LDL cholesterol or lipoprotein(a) alone.
You can also look at fasting insulin and hormonal profiles.
How do you get this data? Your physician can order standard tests, but insurance copays vary. Direct-to-consumer services like Function Health ($365) and InsideTracker ($489/year) offer panels covering 50 to 250+ markers without a doctor’s order.
A warning on the large multi-lab panels: interpretation is the hard part. More data is not always better. Over-testing leads to false positives, unnecessary anxiety, and interventions that solve nothing.
Wearables: Good for Trends, Bad for Diagnostics
Wearables are always-on monitors. The Oura Ring ($349-$499 + membership), Apple Watch ($249-$799+), and WHOOP ($199-$359/year) continuously log heart rate variability, resting heart rate, and sleep staging.
They detect conditions like atrial fibrillation well. They are decent at tracking heart rate trends.
But they lie about details. Wearables consistently overestimate total sleep time. Physical activity intensity measurements show high variability.
Here is the harsh reality: only about 11% of commercially available wearables have been validated for even one biometric outcome.
Despite this, they remain useful. Not for diagnosis. For tracking personal trends over time. If your sleep efficiency drops for three weeks straight, that’s a signal. Whether it’s a device error or real stress is less important than noticing the pattern.
VO₂ Max: The Single Best Longevity Predictor
Cardiorespiratory fitness is now designated a “clinical vital sign” by the American Heart Association. Each 1-MET increase in fitness is linked to a 10%–25% improvement in survival rates.
VO₂ max measures your maximal oxygen uptake during exercise. It might be the single most powerful longevity predictor we have.
The good news: it is highly trainable. At any age.
The bad news: measuring it precisely requires a Cardiopulmonary Exercise Test (CPET). These cost $400–$600 out of pocket at sports clinics.
Consumer wearables estimate VO₂ max using heart rate data. The estimates are imperfect. They correlate reasonably well with measured values, though. Use them to watch your trend line go up. If it stays flat or drops, you need to adjust your training load.
Continuous Glucose Monitoring for Non-Diabetics
Continuous Glucose Monitors (CGMs) were designed for diabetics. Brands like Dexcom Stelo ($99/30 days) and Abbott Lingo ($89/4 weeks) have made them mainstream for the wellness crowd.
The premise is seductive. Watch your blood sugar spike in real-time after eating a bagel. Adjust your diet based on feedback.
The evidence for non-diabetics is murky. A 2026 systematicreview of 23 studies found that CGM use improved mean blood glucose in people with prediabetes. It did not improve glycemic control in healthy, normoglycemic people. There was no effect on BMI.
CGMs are “precision biofeedback tools” within a structured program. For someone with a family history of Type 2 diabetes, the data is invaluable. For a healthy individual, the clinical utility is unproven. It might help you build habits. It might also just create a new obsession.
DEXA Scans: Seeing the Invisible Risk
A DEXA scan measures body composition. Muscle mass. Fat mass. Bone density. And where the fat sits.
This matters because sarcopenia (muscle loss) and osteoporosis kill healthspan. They cause falls. They cause fractures.
Visceral fat — the stuff around your organs — is a stronger cardiovascular risk factor than your total body weight.
The Health, Aging, and Body CompositionStudy showed that declines in lean mass and grip strength are linked to increased mortality over 10–15 years.
Cost? $75–$150 per scan. If you repeat this annually after age 40, you get one of the highest-value insights available. It’s concrete. It’s actionable.
Epigenetic Clocks: Measuring the Pace of Aging
Epigenetic clocks analyze DNA methylation to estimate biological age. They ask: does your biology look your age, older, or younger?
GrimAge and DunedinPACE are top-tier clocks.
A study of Finnish twins tracked over 20 years showed GrimAge predicted mortality independent of smoking, BMI, or chronic disease.
DunedinPACE is more intriguing. It doesn’t just give you an age. It measures your pace of aging. One unit equals one biological year per calendar year. It adds predictive value beyond GrimAge.
Saliva-based tests from TruDiagnostic and Elysium cost $229–$299.
But be careful. There is substantial heterogeneity across clocks. No single model is superior. View these as directional tools. Repeat every 6–12 months. They are not definitive diagnostics.
Physical Performance: The Zero-Cost Metrics
Grip strength. Gait speed. Sit-to-stand repetitions.
These sound boring. They are not.
A meta-analysis of 38 studies (nearly 2 million participants) found that higher grip strength is linked to a 31% lower risk ofall-cause mortality. The link is even stronger in women.
Gait speed under 0.8 meters per second is a strong predictor of adverse outcomes in older adults.
You can buy a hand dynamometer for $30. Use a stopwatch on your phone for gait speed. Track these monthly. The cost is effectively zero. The predictive power is extraordinary.
The Sleep Trap
Sleep is a powerful longevity determinant. It is also heavily neglected.
A UK Biobank study of 407,00+ people showed that sleeping ≤5 hours a night was linked to 25% higher all-cause morality compared to 7 hours.
Total hours are not enough. Look at deep sleep proportion. REM sleep. Timing consistency.
Wearables provide reasonable staging data, though they overestimate total sleep time again.
There is a caveat: Orthosomnia. This is the anxiety caused by tracking sleep. Worrying about your data can worsen your sleep quality. Paradoxical, isn’t it? If the data stresses you out, ignore it. Sleep when you’re tired.
Omics: The Future or The Hype?
Proteomic platforms like SomaLogic’s SomaScan measure 10,000+ proteins simultaneously. They generate “aging clocks” based on plasma proteins.
These clocks predict biological age with high accuracy. They correlate with 18 chronic diseases and mortality.
However, head-to-head tests suggest proteomic clocks perform similarly to epigeetic clocks. Each captures different dimensions of aging.
The most promising future is multi-omics integration: proteomics + metabolomics + epigenetics. Accuracy exceeds 0.90 for predicting Type 2 diabetes or Alzheimer’s.
But right now? Costs are high ($500–$2,000+). The commercial landscape lacks peer-reviewed validation for most consumers. For the average person, these biomarkers are in the early translational stages. Stick to what works.
MRI: The Incidental Finding Minefield
Full-body MRIs from companies like Prenuvo or Ezra cost $1,000–$3,000.
The promise is early cancer detection.
A 2026 review of 9,000+ asymptomatic people found a cancer detection rate of just 1.57%.
What about the rest? 32% of scans showed incidental findings. Most are benign. But benign findings require follow-up. More scans. More biopsies. More anxiety.
Major medical organizations do not endorse routine full-body MRI for asymptomatic people. If you have a BRCA mutation or Li-Fraumeni syndrome, the risk-benefit shifts. For the average healthy adult under50? The juice isn’t worth the squeeze.
Sorting Signal from Noise
With so many options, it is easy to drown.
Sort by evidence quality. Sort by cost.
Physical performance testing and DEXA scans offer the strongest evidence relative to cost. Include these in your routine.
ApoB and hsCRP are worth adding to standard blood work.
Wearables and CGMs are useful for tracking personal trends if you know how to interpret the noise.
Epigenetic clocks, proteomics, and MRI remain promising but lack evidence for most healthy adults. Use them if you can afford the curiosity. They are not essential yet.
Preventive medicine is a long game. Consistently tracking a few well-validated metrics for years beats chasing every new test hit. The trend line matters more than the single data point.
